Acquisitions - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 28, 2019	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Goodwill		$ 140,627,000	$ 140,627,000
Estimated fair value of contingent consideration, short term liabilities		55,345,000	51,382,000
Estimated fair value of contingent consideration, long-term liabilities		95,034,000	102,361,000
Change in fair value of contingent consideration		(3,364,000)	31,842,000	$ 52,793,000
Cobalt Biomedicine, Inc | Acquisition Agreement
Business Acquisition [Line Items]
Business acquisition, percentage of voting interests acquired	100.00%
Goodwill	$ 140,600,000	140,600,000
Maximum contingent consideration upon achievement of certain pre-specified development milestones	500,000,000.0
Cobalt Biomedicine, Inc | Acquisition Agreement | Research and Development Expense
Business Acquisition [Line Items]
Estimated fair value of contingent consideration		150,400,000	153,700,000
Estimated fair value of contingent consideration, short term liabilities		55,400,000	51,400,000
Estimated fair value of contingent consideration, long-term liabilities		95,000,000.0	102,300,000
Change in estimated fair value of success payment		69,300,000	(23,600,000)	(62,300,000)
Change in fair value of contingent consideration		3,400,000	31,800,000	$ 52,800,000
Cobalt Biomedicine, Inc | Acquisition Agreement | Research and Development Expense | Long-term Liabilities
Business Acquisition [Line Items]
Estimated fair value of success payment liability		$ 19,000,000.0	$ 88,300,000
Cobalt Biomedicine, Inc | Acquisition Agreement | Minimum
Business Acquisition [Line Items]
Threshold market capitalization	8,100,000,000
Cobalt Biomedicine, Inc | Acquisition Agreement | Market Capitalization Equal to or Exceeds $8.1 billion
Business Acquisition [Line Items]
Cobalt success payment	500,000,000.0
Cobalt Biomedicine, Inc | Acquisition Agreement | IPR&D
Business Acquisition [Line Items]
Business combination, intangible assets	$ 59,200,000